Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 987 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (treatment C) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Thorough QT/QTc Study

NCT00874237
View directory record Official record
Conditions
Thorough QT/QTc Study
Interventions
Inhaled loxapine, Inhaled placebo, Oral moxifloxacin, Oral placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 28, 2026, 9:37 PM EDT
Recruiting Phase 2 Interventional

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GHZ339, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

NCT01058083
View directory record Official record
Conditions
Dyslipidemia
Interventions
BMS-770767, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

NCT01272830
View directory record Official record
Conditions
Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions
Placebo, Apatone®B
Drug
Lead sponsor
IC-MedTech Corporation
Industry
Eligibility
50 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2Phase 3 Interventional

Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients

NCT01414777
View directory record Official record
Conditions
Hypotension, Pregnancy
Interventions
ondansetron, placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET233, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

NCT00843635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Donald T. Weed
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 28, 2026, 9:37 PM EDT
Not listed Phase 2 Interventional

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687
View directory record Official record
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Study of SCY-635, Pegasys and Copegus in Hepatitis C

NCT01265511
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Placebo, SCY-635, Pegasys, Copegus
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

NCT03077165
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Ilkos Therapeutic Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Colchicine and CRP in Atrial Fibrillation and AF Ablation

NCT01755949
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine, 0.6 mg PO BID, Matching placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 28, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D on Lipids

NCT00723385
View directory record Official record
Conditions
Hypercholesterolemia, Vitamin D Deficiency
Interventions
Vitamin D (1000 or 2000 IU/day), Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

NCT01471717
View directory record Official record
Conditions
Healthy
Interventions
INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 28, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 9:37 PM EDT